So let's say ABBV discounts to $55k (just making this up) for ESRX, then those 117k patients are equivalent to roughly $6.5b in gauranteed revenue from V-Pak, yes? And that is before they add in any other PBMs and Euro GT1b sales... This looks pretty good for ENTA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.